Ligand-Independent EGFR Signaling
- 31 August 2015
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (17), 3436-3441
- https://doi.org/10.1158/0008-5472.can-15-0989
Abstract
Constitutive activation of the EGFR is common in cancer due to EGFR wild-type (EGFRwt) overexpression or the presence of mutant EGFR. Signaling by constitutively active NSCLC EGFR mutants or the EGFRvIII mutant in glioblastoma has been studied intensively and the downstream signals are known. Normally, the EGFRwt is activated when it is exposed to ligand, resulting in activation of canonical signals such as ERK and Akt. The EGFRwt also becomes tyrosine phosphorylated and constitutively activated without ligand when it is overexpressed, but downstream signals are unclear. Recent studies have identified a noncanonical form of signaling triggered by EGFRwt exclusively in the absence of ligand that does not involve ERK or Akt activation but, instead, results in activation of the transcription factor IRF3. The addition of ligand turns off IRF3-dependent transcription and activates ERK and Akt. Thus, the EGFR triggers distinct and mutually exclusive signaling networks, depending on the presence of ligand. Furthermore, noncanonical EGFRwt signaling may influence response to treatment in cancer. Also, there are reports of both synergistic and antagonistic interactions between ligand-dependent EGFRwt and EGFRvIII signaling. Here, we discuss ligand-independent EGFR signal transduction by oncogenic EGFR mutants and EGFRwt, and review the interplay between EGFRwt and EGFRvIII. Cancer Res; 75(17); 3436–41. ©2015 AACR.Keywords
This publication has 50 references indexed in Scilit:
- Opposing Effect of EGFRWT on EGFRvIII-Mediated NF-κB Activation with RIP1 as a Cell Death SwitchCell Reports, 2013
- EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesisActa Neuropathologica, 2013
- Conformational Coupling across the Plasma Membrane in Activation of the EGF ReceptorCell, 2013
- NFKBIADeletion in GlioblastomasThe New England Journal of Medicine, 2011
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapyFEBS Letters, 2010
- Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastomaProceedings of the National Academy of Sciences of the United States of America, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorCell, 2006
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004